European Pharmacovigilance Risk Assessment Committee (PRAC) starts new safety signal procedure with remdesivir

The PRAC has requested an in-depth review of the available data to determine whether use of remdesivir may potentially be associated with reports of sinus bradycardia, following a signal raised by the Italian Medicines Agency.

Source:

European Medicines Agency